Larimar Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -1.28%
- Market cap
- $281.99M
- 104.63M shares
- Filings
- 709
Q1 2020
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2025N/M FY24 yoy
Q3 2026+157.1% FY25 yoy
- $281.99M
- —
- —
- 2.8×
- -40.18%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2019 | 2019-12-31 | $0 | reported | |
| FY 2018 | 2018-12-31 | $0 | reported | |
| FY 2017 | 2017-12-31 | $0 | reported | |
| FY 2016 | 2016-12-31 | $0 | reported | |
| FY 2015 | 2015-12-31 | $0 | reported | |
| FY 2014 | 2014-12-31 | $0 | reported | |
| FY 2013 | 2013-12-31 | $0 | reported | |
| FY 2012 | 2012-12-31 | $0 | reported |
Pharmaceutical preparations
Larimar Therapeutics, Inc. is the 228th largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
NIKANika Pharmaceuticals, Inc———$291.2MVOGXVogenx, Inc.———$283.9MFULCFulcrum Therapeutics, Inc.$0.0100.0%—$282.6MPREPrenetics Global LtdFiscal 2024 figures———$282.0MPRLDPrelude Therapeutics Inc$12.1M73.4%819.6%$280.9M
LRMRLarimar Therapeutics, Inc. (this company)———$280.0M
INOInovio Pharmaceuticals, Inc.$65.3K70.0%130,000.0%$274.4MFTHFaeth Therapeutics, Inc.———$272.4MRCKTRocket Pharmaceuticals, Inc.$0.0——$268.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Larimar Therapeutics, Inc. · CIK 1374690 · Engraved from SEC EDGAR